2 January 2014
Smiths Medical has gained a key US Food and Drug Administration (FDA) approval for a customisable infusion system that helps maintain effective epidural analgesia during labour and delivery or with post-operative pain management.
The FDA 510(k) clearance allows Smiths Medical to market its CADD®-Solis pain management system version 3.0 with Programmed Intermittent Bolus (PIB) and Patient Controlled Analgesics (PCA) delivery in the United States.
PIB medication delivery, using the CADD®-Solis v3.0, consistently administers programmed intermittent boluses (doses) that can be supplemented by the patient, improving pain relief and reducing the need for clinical interventions.
The CADD®-Solis ambulatory infusion system, designed for nurses, anesthesiologists, pharmacists and other hospital personnel, is a state-of-the-art system that meets industry recognised standards for advanced error-reduction features in PCA pumps.
General media enquiries
Contact our global media and communications team at:
Please note – the press team can only answer enquiries from accredited members of the press.
Related articles
Smiths Detection unveils new mobile threat detection technology
Our latest Smiths Group press release outlines news that Smiths Detection has launched a new mobile threat detection screening solution
Find out moreSmiths Detection accelerates partnership with SeeTrue
Read more on Smiths Detection's partnership with SeeTrue, integrating AI technology into its advanced CT security checkpoint systems.
Find out moreJohn Crane awarded 5-year maintenance contract from SK Advanced in South Korea
Read our latest company news as John Crane announces a new 5 year contract with SK Advanced, South Korea
Find out more